Partial volume correction in quantitative amyloid imaging

NeuroImage

Volumn 107, Issue , 2015, Pages 55-64

  Su, Yi ^a   Blazey, Tyler M ^a   Snyder, Abraham Z ^a   Raichle, Marcus E ^a   Marcus, Daniel S ^a   Ances, Beau M ^a   Bateman, Randall J ^a   Cairns, Nigel J ^a   Aldea, Patricia ^a   Cash, Lisa ^a   Christensen, Jon J ^a   Friedrichsen, Karl ^a   Hornbeck, Russ C ^a   Farrar, Angela M ^a   Owen, Christopher J ^a   Mayeux, Richard ^b   Brickman, Adam M ^b   Klunk, William ^c   Price, Julie C ^c   Thompson, Paul M ^d,e   Ghetti, Bernadino ^f   Saykin, Andrew J ^f   Sperling, Reisa A ^g   Johnson, Keith A ^g   Schofield, Peter R ^h,i   Buckles, Virginia ^a   Morris, John C ^a   Benzinger, Tammie L S ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Amyloid imaging; Partial volume correction; PET; PiB

Indexed keywords

AMYLOID; PITTSBURGH COMPOUND B; BENZOTHIAZOLE DERIVATIVE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG RETENTION; FEMALE; HUMAN; IMAGE RECONSTRUCTION; IMAGING; LONGITUDINAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PARTIAL VOLUME CORRECTION; PET SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE AMYLOID IMAGING; QUANTITATIVE DIAGNOSIS; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; ALGORITHM; ALZHEIMER DISEASE; AMYLOID NEUROPATHY; BRAIN CORTEX; COMPUTER SIMULATION; INDIVIDUALITY; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SCINTISCANNING;

ALGORITHMS; ALZHEIMER DISEASE; AMYLOID; AMYLOID NEUROPATHIES; BENZOTHIAZOLES; CEREBRAL CORTEX; COHORT STUDIES; COMPUTER SIMULATION; CROSS-SECTIONAL STUDIES; HUMANS; INDIVIDUALITY; LONGITUDINAL STUDIES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 84917726968     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.11.058     Document Type: Article

References (46)

1. Aisen P.S. Alzheimer's disease therapeutic research: the path forward. Alzheimers Res. Ther. 2009, 1:2.
2. Aisen P.S., Andrieu S., Sampaio C., Carrillo M., Khachaturian Z.S., Dubois B., Feldman H.H., Petersen R.C., Siemers E., Doody R.S., Hendrix S.B., Grundman M., Schneider L.S., Schindler R.J., Salmon E., Potter W.Z., Thomas R.G., Salmon D., Donohue M., Bednar M.M., Touchon J., Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011, 76:280-286.
3. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
5. Bousse A., Pedemonte S., Thomas B.A., Erlandsson K., Ourselin S., Arridge S., Hutton B.F. Markov random field and Gaussian mixture for segmented MRI-based partial volume correction in PET. Phys. Med. Biol. 2012, 57:6681-6705.
6. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3:186-191.
7. Doody R.S., Raman R., Farlow M., Iwatsubo T., Vellas B., Joffe S., Kieburtz K., He F., Sun X., Thomas R.G., Aisen P.S., Siemers E., Sethuraman G., Mohs R. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N. Engl. J. Med. 2013, 369:341-350.
8. Eisenstein S.A., Koller J.M., Piccirillo M., Kim A., Antenor-Dorsey J.A., Videen T.O., Snyder A.Z., Karimi M., Moerlein S.M., Black K.J., Perlmutter J.S., Hershey T. Characterization of extrastriatal D2 in vivo specific binding of [(1)(8)F](N-methyl)benperidol using PET. Synapse 2012, 66:770-780.
9. Frouin V., Comtat C., Reilhac A., Gregoire M.C. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. J. Nucl. Med. 2002, 43:1715-1726.
10. Hajnal J.V., Saeed N., Soar E.J., Oatridge A., Young I.R., Bydder G.M. A registration and interpolation procedure for subvoxel matching of serially acquired MR images. J. Comput. Assist. Tomogr. 1995, 19:289-296.
11. Han X., Jovicich J., Salat D., van der Kouwe A., Quinn B., Czanner S., Busa E., Pacheco J., Albert M., Killiany R., Maguire P., Rosas D., Makris N., Dale A., Dickerson B., Fischl B. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. NeuroImage 2006, 32:180-194.
12. Holtzman D.M., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:77sr1.
13. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
14. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., Whitwell Jennifer L., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 2008, 27:685-691.
15. Jack C.R., Bernstein M.A., Borowski B.J., Gunter J.L., Fox N.C., Thompson P.M., Schuff N., Krueger G., Killiany R.J., Decarli C.S., Dale A.M., Carmichael O.W., Tosun D., Weiner M.W. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2010, 6:212-220.
16. Joshi A., Koeppe R.A., Fessler J.A. Reducing between scanner differences in multi-center PET studies. NeuroImage 2009, 46:154-159.
17. Jovicich J., Czanner S., Han X., Salat D., van der Kouwe A., Quinn B., Pacheco J., Albert M., Killiany R., Blacker D., Maguire P., Rosas D., Makris N., Gollub R., Dale A., Dickerson B.C., Fischl B. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. NeuroImage 2009, 46:177-192.
18. Kim E., Shidahara M., Tsoumpas C., McGinnity C.J., Kwon J.S., Howes O.D., Turkheimer F.E. Partial volume correction using structural-functional synergistic resolution recovery: comparison with geometric transfer matrix method. J. Cereb. Blood Flow Metab. 2013, 33:914-920.
19. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
20. Kuhn F.P., Warnock G.I., Burger C., Ledermann K., Martin-Soelch C., Buck A. Comparison of PET template-based and MRI-based image processing in the quantitative analysis of C11-raclopride PET. EJNMMI Res. 2014, 4:7.
21. Le Pogam A., Hatt M., Descourt P., Boussion N., Tsoumpas C., Turkheimer F.E., Prunier-Aesch C., Baulieu J.L., Guilloteau D., Visvikis D. Evaluation of a 3D local multiresolution algorithm for the correction of partial volume effects in positron emission tomography. Med. Phys. 2011, 38:4920-4923.
22. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990, 10:740-747.
23. Logan J., Fowler J.S., Volkow N.D., Wang G.J., Ding Y.S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996, 16:834-840.
24. Lopresti B.J., Klunk W.E., Mathis C.A., Hoge J.A., Ziolko S.K., Lu X., Meltzer C.C., Schimmel K., Tsopelas N.D., DeKosky S.T., Price J.C. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J. Nucl. Med. 2005, 46:1959-1972.
25. Lowe V.J., Kemp B.J., Jack C.R., Senjem M., Weigand S., Shiung M., Smith G., Knopman D., Boeve B., Mullan B., Petersen R.C. Comparison of 18F-FDG and PiB PET in cognitive impairment. J. Nucl. Med. 2009, 50:878-886.
26. Mathis C.A., Wang Y., Holt D.P., Huang G.F., Debnath M.L., Klunk W.E. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 2003, 46:2740-2754.
27. Meltzer C.C., Zubieta J.K., Brandt J., Tune L.E., Mayberg H.S., Frost J.J. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996, 47:454-461.
28. Meltzer C.C., Kinahan P.E., Greer P.J., Nichols T.E., Comtat C., Cantwell M.N., Lin M.P., Price J.C. Comparative evaluation of MR-based partial-volume correction schemes for PET. J. Nucl. Med. 1999, 40:2053-2065.
29. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
30. Morris J.C., Price A.L. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J. Mol. Neurosci. 2001, 17:101-118.
31. Morris J.C., Aisen P.S., Bateman R.J., Benzinger T.L., Cairns N.J., Fagan A.M., Ghetti B., Goate A.M., Holtzman D.M., Klunk W.E., McDade E., Marcus D.S., Martins R.N., Masters C.L., Mayeux R., Oliver A., Quaid K., Ringman J.M., Rossor M.N., Salloway S., Schofield P.R., Selsor N.J., Sperling R.A., Weiner M.W., Xiong C., Moulder K.L., Buckles V.D. Developing an international network for Alzheimer research: the dominantly inherited Alzheimer network. Clin. Investig. (Lond.) 2012, 2:975-984.
32. Price J.C., Klunk W.E., Lopresti B.J., Lu X., Hoge J.A., Ziolko S.K., Holt D.P., Meltzer C.C., DeKosky S.T., Mathis C.A. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 2005, 25:1528-1547.
33. Rosario B.L., Weissfeld L.A., Laymon C.M., Mathis C.A., Klunk W.E., Berginc M.D., James J.A., Hoge J.A., Price J.C. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. NeuroImage 2011, 55:933-941.
34. Rousset O.G., Ma Y., Evans A.C. Correction for partial volume effects in PET: principle and validation. J. Nucl. Med. 1998, 39:904-911.
35. Rousset O.G., Collins D.L., Rahmim A., Wong D.F. Design and implementation of an automated partial volume correction in PET: application to dopamine receptor quantification in the normal human striatum. J. Nucl. Med. 2008, 49:1097-1106.
36. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Tochon-Danguy H., Chan G., Berlangieri S.U., Jones G., Dickinson-Rowe K.L., Kung H.P., Zhang W., Kung M.P., Skovronsky D., Dyrks T., Holl G., Krause S., Friebe M., Lehman L., Lindemann S., Dinkelborg L.M., Masters C.L., Villemagne V.L. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
37. Rowland D.J., Garbow J.R., Laforest R., Snyder A.Z. Registration of [18F]FDG microPET and small-animal MRI. Nucl. Med. Biol. 2005, 32:567-572.
38. Sojkova J., Zhou Y., An Y., Kraut M.A., Ferrucci L., Wong D.F., Resnick S.M. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch. Neurol. 2011, 68:644-649.
39. Soret M., Bacharach S.L., Buvat I. Partial-volume effect in PET tumor imaging. J. Nucl. Med. 2007, 48:932-945.
40. Su Y., Shoghi K.I. Wavelet denoising in voxel-based parametric estimation of small animal PET images: a systematic evaluation of spatial constraints and noise reduction algorithms. Phys. Med. Biol. 2008, 53:5899-5915.
41. Su Y., D'Angelo G.M., Vlassenko A.G., Zhou G., Snyder A.Z., Marcus D.S., Blazey T.M., Christensen J.J., Vora S., Morris J.C., Mintun M.A., Benzinger T.L. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE 2013, 8:e73377.
42. Thomas B.A., Erlandsson K., Modat M., Thurfjell L., Vandenberghe R., Ourselin S., Hutton B.F. The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:1104-1119.
43. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
44. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
45. Wong D.F., Rosenberg P.B., Zhou Y., Kumar A., Raymont V., Ravert H.T., Dannals R.F., Nandi A., Brasic J.R., Ye W., Hilton J., Lyketsos C., Kung H.F., Joshi A.D., Skovronsky D.M., Pontecorvo M.J. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 2010, 51:913-920.
46. Zaidi H., Ruest T., Schoenahl F., Montandon M.L. Comparative assessment of statistical brain MR image segmentation algorithms and their impact on partial volume correction in PET. NeuroImage 2006, 32:1591-1607.